Skip to content

Discontinued — last reported Q3 '23

Total Revenue at other companies

Eli Lilly logo
Eli LillyLLY
$19.8B+55.5%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$10.26M-79.9%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
$0
Immunome logo
ImmunomeIMNM
$0-100%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$141K+95.8%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$377.33M+1.2%

Other financials

Income statement

See full
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Perspective Therapeutics’s 10-Q, filed November 14, 2023, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's total revenue?
Perspective Therapeutics (CATX) reported total revenue of $2.19M in Q3 2023.
How has Perspective Therapeutics's total revenue changed year-over-year?
Perspective Therapeutics's total revenue increased by 27.3% year-over-year, from $1.72M to $2.19M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.